Inovio Pharmaceuticals (NASDAQ:INO) Price Target Cut to $8.00

Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) had its price target reduced by analysts at Royal Bank of Canada from $11.00 to $8.00 in a report issued on Friday, Benzinga reports. The brokerage presently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target would indicate a potential downside […]

Leave a Reply

Your email address will not be published.

Previous post Crinetics Pharmaceuticals (NASDAQ:CRNX) PT Raised to $69.00 at HC Wainwright
Next post Evanson Asset Management LLC Grows Stock Holdings in Avantis U.S. Equity ETF (NYSEARCA:AVUS)